Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer IRVING, Texas and ALISO VIEJO, Calif., December 4, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, and Ambry Genetics (Ambry),…

Based on data from a prospective, nationwide, multi-center pilot, adding RNA genetic testing to DNA testing identified more disease-causing mutations compared to DNA-only testing. Results from a separate study demonstrated that genetic testing results frequently lead to changes in patient care (Aliso Viejo, CA) November 5, 2019: Ambry Genetics (Ambry), a leading clinical genetic testing…

A new study published in JAMA Network Open demonstrates that RNA genetic testing can substantially improve the interpretation of DNA testing results and improve medical care (Aliso Viejo, CA) October 23, 2019: Ambry Genetics® (Ambry), a leading clinical genetics company, announced today the publication in JAMA Network Open of a study on retrospective RNA genetic…

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results. Separate data showed RNA genetic testing’s ability to clarify the interpretation of complex mutations associated with hereditary cancer risk (Aliso Viejo, CA) October 15, 2019: Ambry Genetics…

+RNAinsight™ will help identify thousands more patients at increased risk for cancer (Aliso Viejo, CA) October 1, 2019: Ambry Genetics® (Ambry), a leading clinical genetic testing company, announced today the launch of +RNAinsight™, a major advancement in genetic testing. +RNAinsight enables clinicians – for the first time ever – to conduct both DNA and RNA genetic…

Study finds that current guidelines exclude too many and test too narrowly, and reveals several new gene-cancer associations with potential to impact patient care. (Aliso Viejo, CA) August 27, 2019: Ambry Genetics (Ambry), a leading clinical genetics testing company, announced today new opportunities to improve genetic testing guidelines. In the largest cohort study of its…

Abstract to be presented at the 2019 American Society of Clinical Oncologists (ASCO) Annual Meeting (Aliso Viejo, CA) May 30, 2019: Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, and Mayo Clinic, have documented significant differences in the prevalence of hereditary genetic mutations, also called germline mutations, linked to breast cancer among…

Data presented at the 2019 American Society of Breast Surgeons (ASBrS) Annual Meeting (Aliso Viejo, CA) May 2, 2019: Researchers from Ambry Genetics (Ambry), a leading clinical genetics testing company, will present results documenting discrepancies between U.S. insurer policies for genetic testing and the 2019 National Comprehensive Cancer Network (NCCN) medical management guidelines for patients at risk…

St. Louis (April 9, 2019) – Intalere, the healthcare industry leader in delivering optimal cost, quality and clinical outcomes, today announced a new partnership with Ambry Genetics, a leading clinical genetic testing company. The collaboration will enable Intalere to offer its healthcare providers access to state-of-the-art clinical genetic testing and family history assessment, so they may…